BRIEF-Inovio's HIV vaccine produces nearly 100 pct immune response rates in clinical study stat : Reuters

J.P. Morgan economist sees modest roll-off caps for Fed's balance sheetNEW YORK, May 25 The U.S. Federal Reserve would set modest initial limits on the amount of Treasuries and mortgage-backed securities to run off its balance sheet later this year, as a part of its effort to remove monetary accommodation, according to a J.P. Morgan economist on Thursday.




Our method makes it possible to analyse and sort HIV viruses in quantities and at speeds that have not been possible before. You take a sample of cells and addfluorescent antibodies that bind to the surface proteins you're interested in. Cells with proteins that are recognised by the antibodies will become fluorescent, while cells lacking such proteins will not. Now researchers at EMBL, ESPCI Paris, and the International AIDS Vaccine Initiative have developed a new technique for rapidly sorting HIV viruses, which could lead to more rapid development of a vaccine for HIV, as they report in Cell Chemical Biology. This enables us to rapidly test millions of viral variants, which should significantly speed up the process of vaccine development.

Inovio's NIH-backed HIV vaccine shows near 100% immune response rate in early test

Data from an early-stage clinical study showed that its Pennvax-GP could elicit an immune response in nearly all participants. The study, supported by the HIV Vaccine Trials Network (HVTN) and NIH's National Institute of Allergy and Infectious Diseases, tested Inovio's DNA vaccine in combination with an immune activator, IL-12. Inovio is one step closer in the race to create an effective HIV vaccine. None of the nine placebo recipients showed an immune response, the investigators report. Since this is the first clinical study of Pennvax-GP, further studies are needed to confirm the vaccine's safety and effectiveness, he said.


collected by :Lucy William

To follow all the new news about Health care